Embecta Corp. Reports Third Quarter Fiscal 2025 Financial Results

Embecta Corp., a global diabetes care company, has released its financial results for the third quarter of fiscal year 2025. The company reported strong performance despite a challenging geopolitical environment, with significant improvements in key financial metrics and operational milestones.

Financial Highlights

For the third quarter ended June 30, 2025, Embecta reported:

• Revenues of $295.5 million, an 8.4% increase on a reported basis and 8.0% on an adjusted constant currency basis.
• Gross profit of $197.1 million with a margin of 66.7%, compared to $190.1 million and 69.8% in the prior year period.
• Operating income of $94.0 million, up from $55.9 million in the prior year period, with a margin of 31.8%.
• Net income of $45.5 million, translating to earnings per diluted share of $0.78, compared to $14.7 million and $0.25 in the prior year period.
• Adjusted EBITDA of $131.0 million, representing a margin of 44.3%, up from $99.2 million and 36.4% in the prior year period.

Business and Operational Highlights

Embecta achieved several operational milestones during the quarter:

• Completed the global transition to its ERP system and operationalized distribution centers and shared services in India.
• Advanced the brand transition program in the U.S. and Canada, expected to be substantially complete by the end of fiscal year 2025.
• Signed multiple contracts with pharmaceutical companies to co-package pen needles with potential generic GLP-1 drugs.
• Continued progress on expanding availability of appropriately sized GLP-1 retail packaging for weekly injection therapies.

Strategic Initiatives and Corporate Developments

Key strategic initiatives and corporate developments include:

• Substantially completed a restructuring plan to streamline the organization, expected to generate pre-tax cost savings of $7-8 million in the second half of fiscal year 2025.
• Reduced debt by approximately $52.4 million during the third quarter, achieving a total year-to-date debt reduction of $112 million.
• Announced a quarterly cash dividend of $0.15 per share, payable on September 15, 2025.

Management's Perspective

Devdatt (Dev) Kurdikar, President and CEO of Embecta, commented on the results, stating, "Q3 was a strong quarter for Embecta, reflecting solid commercial execution, aided in part by the timing of customer orders. Despite an increasingly complex and dynamic geopolitical environment, given the year-to-date performance and our outlook for the remainder of the year, we are tightening and raising our fiscal 2025 outlook for key financial metrics."

Future Outlook

For fiscal year 2025, Embecta has updated its financial guidance:

• Reported revenues are expected to be between $1,078 million and $1,085 million.
• Adjusted earnings per diluted share are projected to be in the range of $2.90 to $2.95.
• Adjusted EBITDA margin is anticipated to be between 37.25% and 37.50%.

SEC Filing: Embecta Corp. [ EMBC ] - 8-K - Aug. 08, 2025